Professor Tim Eisen
 |
University positionProfessor Professor Tim Eisen is pleased to consider applications from prospective PhD students. |
DepartmentsInstitutes |
Research ThemesClinical trials Clinical consultation |
Interests
I am a clinical triallist interested in developing new treatments for advanced disease, ideentifying and managing those at risk of disease. My special clinical areas are kidney cancer, lung cancer and melanoma.
In kidney cancer and melanoma I have been particularly involved in the development of tyrosine kinase inhibitors as therapeutic agents.
Research Focus
Keywords
Cancer sites
Equipment
Key publications
*Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2): 125–34
*Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581 6,
*Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, Bridle H, Eisen T*, Houlston RS*; GELCAPS Consortium. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006 Jun;16(6):693–701. *denotes joint PI
Collaborators
United Kingdom
Richard Houlston
International
Richard Marais